Latest Health Care News

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Wellnex Life Limited has announced a non-renounceable entitlement offer to raise approximately $22.1 million at $0.65 per share, supporting its planned AIM listing and strategic growth initiatives.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

Australian Foundation Investment Company (AFIC) reported a 2.7% rise in half-year profit to $154.2 million and increased its interim dividend to 12 cents per share, while its portfolio outpaced the S&P/ASX 200 over the past year.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.